Hims & Hers Health Inc. (HIMS) 今日夜盘股价大涨5.61%，引起了市场的广泛关注。
消息面上，推动股价上涨的主要催化剂包括：丹麦制药巨头诺和诺德宣布与Hims达成合作，将在其平台销售减肥药物；以及美国食品药品监督管理局(FDA)宣布计划将12种肽类药物从二级限制清单中移除，并拟于7月召开专家会议讨论复方药房生产肽类药物的可行性。这两大利好消息显著提升了市场对该公司未来增长潜力的预期。
尽管该股在日间交易时段曾出现回调，但夜盘交易中市场情绪再度转向积极，反映了投资者对上述长期利好消息的持续认可。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.